Not much is known about the reasons for the moderate responsiveness of STS in the clinic. Stein et al (1996) reviewed 18 studies on the expression of pI70-glycoprotein (Pgp) or the MDRI gene in bone sarcomas and STS. The intrinsic expression of the MDRJ gene in untreated tumours appeared to be extremely variable. with an average of 43% of positive cases. In contrast to childhood STS. a significant correlation with the response to chemotherapy was not found in adult STS. Far less is known about the possible implication of other drug resistance mechanisms in STS. Such mechanisms may include alteration of DNA topoisomerase H. which is the nuclear target for doxorubicin and etoposide (Nitiis and Beck. 1996) or glutathione and glutathionedependent enzymes involved in the detoxification of alkylating agents such as cyclophosphamide and ifosfamide (Black and Wolf. 1991; Tew. 1994: Hayes and Pulford. 1995) .
In the last few years. we have established several human tumour xenografts derived from adult STS for subcutaneous (s.c.) growth in the nude mouse. These xenografts were analysed for their response to anti-cancer agents commonly in use in the clinic. In an attempt to identify the mechanisms underlying the moderate chemosensitivity of STS. we assessed the expression of the MDRJ gene. topoisomerase Ila expression. the glutathione content and the activities of glutathione-dependent enzymes. The outcome of these parameters was compared with the in vivo response to the individual anti-cancer agents.
Characterizati of soft tissue sarcorma xenografts 1587 
MATERIALS AND METHODS Animals and transplantation
Female athymic nude mice (NMRI/Cpb or Hsd:Athymic Nude-nu) were purchased from Harlan CPB (Zeist, The Netherlands) at the age of 6 weeks. Animals were maintained in isolation in cages with paper filter covers under controlled atmospheric conditions. (Feit et al. 1984) .
Human origin of STS xenografts
Tumour tissue of patients was examined by light microscopy. immunohistochemistry and electron microscopy. The residual part of the tissue used for transplantation as well as tumour samples of further passages in the mouse were subjected to light microscopy. Staining of paraffim-embedded sections included haematoxylineosin. periodic acid Schiff (PAS). PAS-diastase and alcian blue. In each passage. tumour samples were compared with the tumour of origin for retention of the histological appearance. Analysis of the lactate dehydrogenase (LDH) isoenzyme pattem was carried out in all established xenografts. Briefly. 500 mg of tumour tissue was minced mechanically in 2.5 ml 0.05 M sodium barbital buffer (pH 8.6). After centrifugation. 7 tl of the supernatant was prepared for electrophoresis by means of the Paragon LDH Isoenzyme Electrophoresis Kit (Beckman. Fullerton. CA. USA). Human serum and serum from non-tumour-bearing mice were used as controls.
Drugs and treatnent
Doxorubicin (Farmitalia Carlo Erba. Nivelles. Belgium) dissolved in water 2 mg ml-I and vincristine 1 mg ml-' (Eli Lilly. Nieuwegein.
The Netherlands) diluted in sodium chloride 0.9% to 0.2 mg ml-' were injected i.v. weekly for 2 weeks at the respective doses of 8 mg kg-' and I mg kg-'. Cyclophosphamide (ASTA-Medica. Frankfurt. Germany) dissolved in water 50 mg ml-'and ifosfamide (ASTA) dissolved in water 20 mg ml-' were given i.p. twice with 2 weeks in between at the respective doses of 150 mg kg' and 250 mg kg-' within 3 h of drug preparation. Etoposide 20 mg ml-' (Bristol-Myers Squibb. Woerden. The Netherlands) was further diluted in sodium chloride 0.9% to I mg ml-' and was administred at a dose of 7 mg kg-' i.p. daily x 5. Drug doses were maximum tolerated in the schedules applied in our laboratory and published earlier for doxorubicin. vincristine. cyclophosphamide and ifosfamide (Boven et al. 1989 (Boven et al. . 1990 . At the maximum tolerated dose. tumourbearing nude mice showed a reversible weight loss of 10-15% of the initial weight within 2 weeks after the initiation of ratment the efficacy as a ratio between teated (T) and control (C) tuhmo (T/C x 100%). Growth inhibition was expressed as 100% -(T/C x 100%). T'he highest percentage reached on a particular day within 5 weeks after the last drug administration was considered the optimal growth inhibition. Tumours that had not reached 20 mm at the start of treatment were considered inevaluable. Complete remissions represented tumours that were not visible for a period of at least 4 weeks. Animals dying within 2 weeks after the final injection were considered toxic deaths and were excluded from the evaluation. A drug was considered to be active when the growth inhibition was > 50%7c. very active > 75% and inactive if the growth inhibition was < 50% (Boven et al. 1988 ). (Klumper et al. 1995) . For both the MDRJ gene and topoisomerase IHa expression a y-actin probe was included as a control for RNA recovery. The hybridized probes were visualized after electrophoresis through a denaturing 6% acrylamide gel. followed by autoradiography (exposure to Kodak XS film overnight at -70°C). The amount of MDRJ and topoisomerase IHa mRNA relative to the amount of yactin was calculated by densitometric scanning of autoradiograms.
MDR1 and topoisomerase Ila expression
Glutathione and glutathione-dependent enzymes For determination of glutathione contents and of glutathionedependent enzymes. the tissues from three separate tumours per STS xenograft. stored at -70°C. were thawed and subsequent procedures were carried out on ice. Each sample was homogenized for 60 s in 1 ml of 0.2 .M potassium phosphate buffer at pH 6.5 (Omni-1000 homogenizer. Omni International. Waterbury CT.
USA). Supernatants of homogenates were collected after centrifugation at 100 000 g for 60 min and immediately used for enzyme determination. The total protein content was determined with the BCA protein assay reagent (Pierce Europe. Rockford. IL. USA).
Bovine serum albumin was used for standardization. Total glutathione was measured by high-performance liquid chromatography (HPLC) (Waters. Milford. MA. USA) as described previously (Neuschwander-Tetri and Roll. 1989 ). Peaks were detected by fluorescence at 420 nm after excitation at 340 nm and compared with a standard glutathione curve. Laswrence and Burk ( 1976) . After starting, the reaction A ith the addition of t-butyl hydroperoxide. the rate of the decrease in extinction at 340 nm w-as determined. For measurement of glutathione reductase. oxidized glutathione % as added to the sample in the presence of NADPH. as described by Carlberg and Mannervik (1985) . The decrease in extinction at 340 nm was measured to express the activity of glutathione reductase. Glutathione and glutathione-dependent enzymes Glutathione concentrations xaried betxeen 9.4 and 67.7 nmol mo-l protein in the ten STS xenografts (Table 3 ). The xaniation in 2lutathione S-transferase enzyme actixvity xxas more pronounced than the differences in glutathione peroxidase and reductase actixities among the xenografts. (Boven et al. 1988 ). Subsequent studies have revealed that screening of new drugs in a disease-oriented approach becomes feasible with the use of these guidelines (Boven et al. 1992: Langdon et al. 1994). Our panel of human STS xenografts appears to be a valuable addition to the system of secondary drug testing.
Human tumour xenografts are an elegant tool to compare the efficacy of new analogues with that of the parent compounds (Boven. 1991b) . Tbere are. however. some disadvantages related to differences between species. because the phamacology and the sideeffects of the analogue may follow a different pattem than those of the parent compound-Pefraps ifosfamide is such a compound because.
unlike in STS patients. we could not confirm its superiority to cyclophosphamide. This may be explained by differences in drug doses tolerated which was for ifosfamide 1.7-fold higher than for cyclophosphamide in the mouse. whereas ifosfamide in patients can be dosed five times higher than cyclophosphamide upon mesna uroprotection. Treatment (Stein etal. 1996 Cellular glutathione levels are a determinant for sensitivity to alkylating agents and significant glutathione S-transferase activity has been found in tumour cells intrinsically resistant to such drugs (Black and Wolf. 1991; Tew. 1994: Hayes and Pulford. 1995) . It has been suggested that elevated glutathione S-transferase x isoenzyme levels are a marker for drug resistance (Black and Wolf. 1991). The roles of glutathione peroxidase and reductase in drug resistance are less clear (Black and Wolf. 1991) . Most information on glutathione and glutathione-dependent enzymes in unselected cell lines has been obtained by measuring the sensitivity to cisplatin. In eight human small-cell lung cancer cell lines. Sharma et al (1993) have described that of the four parameters measured only glutathione S-transferase activity correlated with the degree of cisplatin resistance. Hida et al (1993) have reported higher glutathione S-transferase xc levels in human lung cancer cell lines with low sensitivity to cisplatin. In cell lines from head and neck cancer. Yellin et al (1994) have found an inverse relationship between cisplatin sensitivity and glutathione contents. but not glutathione S-transferase it mRNA expression. We compared glutathione concentrations and glutathione-dependent enzyme activities with the in vivo sensitivity to cyclophosphamide and ifosfamide. but no correlations could be found. However. levels of glutathione and glutathione S-transferase activity in the human ovarian cancer xenograft were low to intennediate when compared with values in STS lines. whereas in MRI-H-207 tumours the alkylating agents could induce complete remissions.
Our panel of human STS xenografts grown as s.c. tumours reflects the clinic in terms of retention of the histoloy,. human LDH isoenzymes and chemosensitivity pattem. The drug resistance characteristics examined in these xenografts do not explain the reasons for the moderate responsiveness of STS to the various anti-cancer agents tested. Topoisomerase Ila mRNA levels were relatively low. which may partly account for intrinsic resistance against e.g. doxorubicin. DNA repair mechanisms may possibly contribute to the moderate responsiveness to alkylating agents. Doxorubicin resistance has been observed in tumour cells that express the major vault protein encoded by LRP (Slovak et al. 1995) or the multidrug resistance-associated protein MRP (Cole et al. 1994 ). Our STS xenografts will probably be of value in elucidating other disease-related resistance mechanisms. towards which compounds may be generated that improve the treatment outcome in this malignancy.
